WO2006130613A3 - Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases - Google Patents

Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases Download PDF

Info

Publication number
WO2006130613A3
WO2006130613A3 PCT/US2006/020986 US2006020986W WO2006130613A3 WO 2006130613 A3 WO2006130613 A3 WO 2006130613A3 US 2006020986 W US2006020986 W US 2006020986W WO 2006130613 A3 WO2006130613 A3 WO 2006130613A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
protein kinase
substituted
derivatives
cancer
Prior art date
Application number
PCT/US2006/020986
Other languages
French (fr)
Other versions
WO2006130613A2 (en
Inventor
Yang Young
Pranee Young
Martin Miranda
Michaela Pfahl
Bruce Carter
Mubarack Muthalif
Magnus Pfahl
Original Assignee
Pfahl Family Trust Dated 9 Jul
Yang Young
Pranee Young
Martin Miranda
Michaela Pfahl
Bruce Carter
Mubarack Muthalif
Magnus Pfahl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfahl Family Trust Dated 9 Jul, Yang Young, Pranee Young, Martin Miranda, Michaela Pfahl, Bruce Carter, Mubarack Muthalif, Magnus Pfahl filed Critical Pfahl Family Trust Dated 9 Jul
Priority to EP06771644A priority Critical patent/EP1896462A2/en
Priority to AU2006252629A priority patent/AU2006252629A1/en
Priority to CA002650999A priority patent/CA2650999A1/en
Priority to JP2008514781A priority patent/JP2008542382A/en
Publication of WO2006130613A2 publication Critical patent/WO2006130613A2/en
Publication of WO2006130613A3 publication Critical patent/WO2006130613A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention is directed to certain patentable substituted benzoxazole derivatives that exhibit protein kinase (PK) inhibition activity or modulating ability. Pharmaceutical compositions comprising these compounds, and methods for preparing and using them, are also described. For example, these heterocyclic compounds are useful in treating disorders related to abnormal PK activity, including diseases and disorders involving aberrant cell proliferation, for example, AML, CML, gastrointestinal stromal cancers, thyroid cancer, other cancers and leukemias, as well as other diseases such as inflammation and atherosclerosis.
PCT/US2006/020986 2005-05-31 2006-05-30 Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases WO2006130613A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06771644A EP1896462A2 (en) 2005-05-31 2006-05-30 Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
AU2006252629A AU2006252629A1 (en) 2005-05-31 2006-05-30 Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
CA002650999A CA2650999A1 (en) 2005-05-31 2006-05-30 Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
JP2008514781A JP2008542382A (en) 2005-05-31 2006-05-30 Substituted biaryl heterocyclic derivatives as protein kinase inhibitors for the treatment of cancer and other diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68606205P 2005-05-31 2005-05-31
US60/686,062 2005-05-31

Publications (2)

Publication Number Publication Date
WO2006130613A2 WO2006130613A2 (en) 2006-12-07
WO2006130613A3 true WO2006130613A3 (en) 2007-02-08

Family

ID=37482228

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020986 WO2006130613A2 (en) 2005-05-31 2006-05-30 Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases

Country Status (6)

Country Link
EP (1) EP1896462A2 (en)
JP (1) JP2008542382A (en)
CN (1) CN101233129A (en)
AU (1) AU2006252629A1 (en)
CA (1) CA2650999A1 (en)
WO (1) WO2006130613A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
DK2630259T3 (en) * 2010-10-20 2015-07-06 Univ Bordeaux SIGNATURES OF CLINICAL OUTCOME In gastrointestinal stromal tumors AND METHOD FOR THE TREATMENT OF gastrointestinal stromal tumors
AU2016291676B2 (en) 2015-07-16 2020-04-30 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
JOP20190077A1 (en) 2016-10-10 2019-04-09 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI704148B (en) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (en) 2017-03-16 2019-09-16 Array Biopharma Inc Macrocyclic compounds as ros1 kinase inhibitors
TW202410896A (en) 2017-10-10 2024-03-16 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TWI802635B (en) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
CN112996794A (en) 2018-09-10 2021-06-18 阿雷生物药品公司 Fused heterocyclic compounds as RET kinase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545026B1 (en) * 1999-08-23 2003-04-08 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545026B1 (en) * 1999-08-23 2003-04-08 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

Also Published As

Publication number Publication date
AU2006252629A1 (en) 2006-12-07
WO2006130613A2 (en) 2006-12-07
CA2650999A1 (en) 2006-12-07
EP1896462A2 (en) 2008-03-12
JP2008542382A (en) 2008-11-27
CN101233129A (en) 2008-07-30

Similar Documents

Publication Publication Date Title
WO2006130613A3 (en) Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
EA200701930A1 (en) Derivatives of pyrimidine for the treatment of hyperproliferative disorders
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2008024977A3 (en) Isoquinoline, quinazoline and phthalazine derivatives
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA200701808A1 (en) Derivatives of tetrahydroindolone and tetrahydroindazole
EA201270215A1 (en) APAF-1 INHIBITOR COMPOUNDS
WO2007035620A3 (en) Carbazole derivatives
MX2009006706A (en) Bicyclic heterocyclic compounds as fgfr inhibitors.
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
WO2007044724A3 (en) Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
IN2014KN02886A (en)
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
UA100007C2 (en) Heterocyclic inhibitors of mek, use thereof and pharmaceutical composition containing thereof
EA200802050A1 (en) NEW HETEROARYLIC-SUBSTITUTED ARYLAMINOPIRIDINE DERIVATIVES AS MEK INHIBITORS
MX2010009207A (en) Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors.
MX2010007714A (en) Fused pyridines active as inhibitors of c-met.
TW200745066A (en) Novel PTP1B inhibitors
EA200901483A1 (en) DERIVATIVES OF PYRIMIDINE AND CONTAINING THEIR COMPOSITIONS AS KINASE C-KIT AND PDGFR INHIBITORS
MX2007004248A (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2008001538A (en) 2-aminoaryl pyridines as protein kinases inhibitors.
SI2054418T1 (en) Dihydrothieno pyrimidines as akt protein kinase inhibitors
AU2006273692A8 (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680028185.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2008514781

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006252629

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006771644

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 9969/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2006252629

Country of ref document: AU

Date of ref document: 20060530

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2650999

Country of ref document: CA